Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Olaparib in Biochemically Recurrent Prostate Cancer
NCT04336943Phase 2Terminated
- Sponsor
- University of Washington
- Start
- Apr 2021
- Primary completion
- Jun 2024
- Modality
- Antibody Conjugates, Small Molecules, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, olaparib in prostate cancer (PCa), sponsored by University of Washington. Started Apr 2021; status: terminated.
02
Drugs
durvalumabolaparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04336943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04336943.